Silverfin false false 30/04/2024 01/05/2023 30/04/2024 Mr S Birrell 08/04/2014 21 January 2025 The principal activity of the Company during the financial year continued to be that of consultancy services to the pharmaceutical industry. SC474687 2024-04-30 SC474687 bus:Director1 2024-04-30 SC474687 2023-04-30 SC474687 core:CurrentFinancialInstruments 2024-04-30 SC474687 core:CurrentFinancialInstruments 2023-04-30 SC474687 core:Non-currentFinancialInstruments 2024-04-30 SC474687 core:Non-currentFinancialInstruments 2023-04-30 SC474687 core:ShareCapital 2024-04-30 SC474687 core:ShareCapital 2023-04-30 SC474687 core:RetainedEarningsAccumulatedLosses 2024-04-30 SC474687 core:RetainedEarningsAccumulatedLosses 2023-04-30 SC474687 core:FurnitureFittings 2023-04-30 SC474687 core:FurnitureFittings 2024-04-30 SC474687 bus:OrdinaryShareClass1 2024-04-30 SC474687 2023-05-01 2024-04-30 SC474687 bus:FilletedAccounts 2023-05-01 2024-04-30 SC474687 bus:SmallEntities 2023-05-01 2024-04-30 SC474687 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 SC474687 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 SC474687 bus:Director1 2023-05-01 2024-04-30 SC474687 core:FurnitureFittings core:TopRangeValue 2023-05-01 2024-04-30 SC474687 2022-05-01 2023-04-30 SC474687 core:FurnitureFittings 2023-05-01 2024-04-30 SC474687 core:CurrentFinancialInstruments 2023-05-01 2024-04-30 SC474687 core:Non-currentFinancialInstruments 2023-05-01 2024-04-30 SC474687 bus:OrdinaryShareClass1 2023-05-01 2024-04-30 SC474687 bus:OrdinaryShareClass1 2022-05-01 2023-04-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: SC474687 (Scotland)

STONEBRIDGE CLINICAL LIMITED

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 APRIL 2024
PAGES FOR FILING WITH THE REGISTRAR

STONEBRIDGE CLINICAL LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 APRIL 2024

Contents

STONEBRIDGE CLINICAL LIMITED

BALANCE SHEET

AS AT 30 APRIL 2024
STONEBRIDGE CLINICAL LIMITED

BALANCE SHEET (continued)

AS AT 30 APRIL 2024
Note 2024 2023
£ £
Fixed assets
Tangible assets 3 486 957
486 957
Current assets
Debtors 4 6,992 9,327
Cash at bank and in hand 33,429 15,901
40,421 25,228
Creditors: amounts falling due within one year 5 ( 14,601) ( 13,131)
Net current assets 25,820 12,097
Total assets less current liabilities 26,306 13,054
Creditors: amounts falling due after more than one year 6 ( 7,000) ( 13,000)
Net assets 19,306 54
Capital and reserves
Called-up share capital 7 10 10
Profit and loss account 19,296 44
Total shareholders' funds 19,306 54

For the financial year ending 30 April 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Stonebridge Clinical Limited (registered number: SC474687) were approved and authorised for issue by the Director on 21 January 2025. They were signed on its behalf by:

Mr S Birrell
Director
STONEBRIDGE CLINICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 APRIL 2024
STONEBRIDGE CLINICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 APRIL 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Stonebridge Clinical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Scotland. The address of the Company's registered office is 272 Bath Street, Glasgow, G2 4JR, United Kingdom.

The financial statements have been prepared under the historical cost convention and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for consultancy services provided to the pharmaceutical industry, and is shown net of VAT.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Employee benefits

Short term benefits
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised as an expense when the Company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Tangible fixed assets

Tangible fixed assets are stated at cost, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Fixtures and fittings 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are measured at transaction price including transaction costs.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities
Basic financial liabilities, including creditors and bank loans, are initially recognised at transaction price.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 2 2

3. Tangible assets

Fixtures and fittings Total
£ £
Cost
At 01 May 2023 2,371 2,371
Additions 109 109
Disposals ( 117) ( 117)
At 30 April 2024 2,363 2,363
Accumulated depreciation
At 01 May 2023 1,414 1,414
Charge for the financial year 580 580
Disposals ( 117) ( 117)
At 30 April 2024 1,877 1,877
Net book value
At 30 April 2024 486 486
At 30 April 2023 957 957

4. Debtors

2024 2023
£ £
Trade debtors 5,082 1,617
Other debtors 1,910 7,710
6,992 9,327

5. Creditors: amounts falling due within one year

2024 2023
£ £
Bank loans 6,000 6,000
Taxation and social security 6,975 5,541
Other creditors 1,626 1,590
14,601 13,131

There are no amounts included above in respect of which any security has been given by the small entity.

6. Creditors: amounts falling due after more than one year

2024 2023
£ £
Bank loans 7,000 13,000

There are no amounts included above in respect of which any security has been given by the small entity.

7. Called-up share capital

2024 2023
£ £
Allotted, called-up and fully-paid
10 Ordinary shares of £ 1.00 each 10 10

8. Related party transactions

Transactions with the entity's director

2024 2023
£ £
Amounts due from related party 1,900 7,700

The above amounts are unsecured, interest-free and repayable on demand.